Enlivex Therapeutics Ltd (ENLV)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $1.72M
Last updated: Nov 17, 2026 at 4:26 PM ET
Enlivex Therapeutics Ltd (ENLV) Statistics
Enlivex Therapeutics (ENLV) has a market cap of $1.72M and an enterprise value of $13.07M. Its share count is up 1115.64% from a year earlier. Its net debt of $11.36M equals 662.02% of its market cap.
Total Valuation
Enterprise value is 662.02% above the market cap, as debt exceeds cash.
| Market Cap | $1.72M |
|---|---|
| Enterprise Value | $13.07M |
| Latest price (Nov 17, 2026) | $1.15 |
Key Dates
The next earnings report is expected on Mar 23, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Mar 23, 2027 (expected) |
|---|---|
| Last Earnings Date | Sep 4, 2026 |
| Fiscal Year End | December |
Price Statistics
The stock is down 99.52% over 52 weeks and trades 79.97% below its 50-day average.
| Beta (1Y) | 1.71 |
|---|---|
| 52-Week Change | -99.52% |
| 1-Month Change | -65.34% |
| 3-Month Change | -95.85% |
| 6-Month Change | -99.32% |
| 5-Year Change | -99.91% |
| 10-Year Change | -99.99% |
| Total Return (1Y) | -99.52% |
| Total Return (3Y CAGR) | -85.98% |
| Total Return (5Y CAGR) | -77.48% |
| Return vs SPY (1Y) | -111.07% |
| Max Drawdown (1Y) | -99.61% |
| Max Drawdown (3Y) | -99.89% |
| Sharpe Ratio (1Y) | -4.56 |
| Correlation with SPY (1Y) | 0.20 |
| 50-Day Average | $5.74 |
| 200-Day Average | $124.31 |
| 52-Week Range | $1.00 to $316.80 |
| RSI (14 Days) | 14.9 |
| Average Volume (20 Days) | 157.51K |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 119.39x current liabilities, and total debt is 0.00x shareholder equity.
| Current Ratio | 119.39x |
|---|---|
| Quick Ratio | 119.39x |
| Debt / Equity | 0.00x |
Returns and Efficiency
Return on invested capital is -0.30% over the last 12 months, against a 5-year average of -41.15%.
| Return on Equity (ROE) | 80.31% |
|---|---|
| Return on Assets (ROA) | 63.89% |
| Return on Invested Capital (ROIC) | -0.30% |
| ROE (5Y Average) | -33.61% |
| ROA (5Y Average) | -28.24% |
| ROIC (5Y Average) | -41.15% |
Taxes
Income tax took 23.23% of pretax income over the last 12 months.
| Income Tax (TTM) | $1.24B |
|---|---|
| Effective Tax Rate | 23.23% |
Scores
ENLV has a Piotroski F-Score of 3 of 9, in the average band of 3 to 7.
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Piotroski F-Score | 3 of 9 |
|---|---|
| Piotroski Strength | Average |
Income Statement
| Operating Income | -$20.56M |
|---|---|
| Pretax Income | $5.35B |
| Net Income | $4.11B |
| Reported EPS (TTM) | -$65.76 |
Trailing 12 months through Jun 30, 2026.
Balance Sheet
Shareholder equity funds 79.59% of the $4.90B in total assets.
| Cash and Equivalents | $5.52M |
|---|---|
| Total Debt | $16.88M |
| Net Debt | $11.36M |
| Net Debt Per Share | $9.40 |
| Working Capital | $3.72B |
| Shareholder Equity | $3.90B |
| Book Value Per Share | $3,226.12 |
| Tangible Book Value | $2.75B |
| Tangible Book Per Share | $2,277.04 |
| Total Assets | $4.90B |
| Total Liabilities | $1.00B |
Balance sheet as of Jun 30, 2026.
Cash Flow
After $39.38K of capital spending, operating cash flow left -$15.84M of free cash flow.
| Operating Cash Flow | -$15.80M |
|---|---|
| Capital Expenditures | $39.38K |
| Free Cash Flow | -$15.84M |
| FCF Per Share | -$10.34 |
| Depreciation and Amortization | $346.00K |
Trailing 12 months through Jun 30, 2026.
Growth
| Book Value Per Share Growth (2Y CAGR) | +7617.83% |
|---|---|
| Tangible Book Per Share Growth (2Y CAGR) | +6352.38% |
Dividends and Yields
ENLV does not pay a dividend. Its free cash flow yield is -1140.21%.
| FCF Yield | -1140.21% |
|---|---|
| Shareholder Yield | 0.00% |
Stock Splits
The last split was a 1-for-16 reverse split on Oct 27, 2026.
| Last Split Date | Oct 27, 2026 |
|---|---|
| Split Type | Reverse split |
| Split Ratio | 1:16 |
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About ENLV
What is ENLV's market cap?
Enlivex Therapeutics has a market cap of $1.72M. Its enterprise value, which adds debt and subtracts cash, is $13.07M.
How many shares of ENLV are outstanding?
Enlivex Therapeutics has 1.21M shares outstanding. The count is up 1115.64% from a year earlier.
Does ENLV pay a dividend?
No. Enlivex Therapeutics does not pay a dividend.
How much debt does ENLV have?
Enlivex Therapeutics has $16.88M of total debt and $5.52M of cash and equivalents, a net debt position of $11.36M.
ENLV pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Competitors